Sign In
Buy NMRD
$0.0002
+0 (+0%)
At Close: Jun 03, 2026
Reviewing InfuSystem (NYSE:INFU) and Nemaura Medical (OTCMKTS:NMRD)
02:36am, Monday, 09'th Mar 2026
InfuSystem (NYSE: INFU - Get Free Report) and Nemaura Medical (OTCMKTS:NMRD - Get Free Report) are both medical companies, but which is the better stock? We will contrast the two businesses based on t
Important Update on Listing Status and Strategic Direction
07:00am, Wednesday, 03'rd Jan 2024
Loughborough, UK, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Nemaura Medical Inc. (“Nemaura Medical” or the “Company”), developer of a daily wear non-invasive glucose sensor, and digital healthcare pro
Nemaura Medical Inc. Receives Positive Nasdaq Listing Decision
08:00am, Wednesday, 13'th Dec 2023
Loughborough, UK, Dec. 13, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical Inc. (NASDAQ: NMRD) (“Nemaura Medical” or the “Company”), developer of a daily wear non-invasive glucose sensor, and digital
Nemaura Medical Inc. Secures $10 Million Non-Dilutive Credit Facility to Fuel Strategic Growth
08:30am, Tuesday, 21'st Nov 2023
Loughborough, UK, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical Inc. (NASDAQ: NMRD) (“Nemaura Medical” or the “Company”), developer of a daily wear non-invasive glucose sensor, and digital
Nemaura (NMRD) to Expand in UK With Metabolic Health Program
12:47pm, Friday, 17'th Nov 2023
The latest program leverages Nemaura's (NMRD) world-first daily wear non-invasive CGM technology, providing individuals with real-time insights into their body's glucose dynamics.
Nemaura Launches Direct to Consumer Offering of Metabolic Health Program in Combination with GLP-1 Weight Loss Drugs
08:00am, Tuesday, 14'th Nov 2023
Company CEO to discuss development at 1pm EST on 15 th November 2023, at the Sidoti Virtual Investor Conference
Nemaura Medical Reports Fiscal Second Quarter 2024 Results and Provides Business Update
04:14pm, Monday, 13'th Nov 2023
Loughborough, England, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (Nasdaq: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializi
LOUGHBOROUGH, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc.(NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercialising non-in
Nemaura Medical to Present at the Maxim Group Emerging Growth in A.I. Conference
09:15am, Monday, 18'th Sep 2023
Loughborough, England, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic
Nemaura Medical Provides Update on Nasdaq Compliance Status and Process
08:00am, Thursday, 14'th Sep 2023
LOUGHBOROUGH, Sept. 14, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc.(Nasdaq: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercialising non-in
Best Penny Stocks To Buy Now? 10 Under $1 To Watch
01:05pm, Wednesday, 13'th Sep 2023
Let's be honest – penny stocks priced at less than a buck hold an irresistible appeal. Even a small investment could potentially lead to insane returns.
LOUGHBOROUGH, Sept. 13, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc.(NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercialising non-in
Nemaura Medical Announces Participation at HLTH 2023, Las Vegas
09:26am, Tuesday, 12'th Sep 2023
LOUGHBOROUGH, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc.(NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercialising non-in
Nemaura Medical Completes 100 Patient Study for sugarBEAT® 24-hour Wear and Reports Interim Results
09:00am, Monday, 11'th Sep 2023
LOUGHBOROUGH, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non-i
Nemaura Medical, Inc. (NMRD) Upgraded to Buy: What Does It Mean for the Stock?
01:32pm, Wednesday, 23'rd Aug 2023
Nemaura Medical, Inc. (NMRD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
